Korea AZ-Jinhungwon Announces Research Project Call for Comprehensive Diabetes Management

'KHIDI-AZ Diabetes Research Support Program'
Research funding up to 60 million KRW and AZ networking provided

Korea AstraZeneca (AZ) announced on the 31st that it is inviting research proposals for the 3rd 'KHIDI-AZ Diabetes Research Support Program' in collaboration with the Korea Health Industry Development Institute (KHIDI) to contribute to the activation of comprehensive diabetes management research and to discover outstanding researchers.

This call is open to domestic researchers capable of conducting clinical and basic research on diabetes, covering prevention, treatment, management, and complication control. Applicants can check information on the KHIDI website from November 1 to 27 and submit their applications via email. Selected institutions will receive research funding of up to 60 million KRW along with networking opportunities with AZ’s global research and development (R&D) organization and partner researchers.

Launched in 2021 by Korea AZ and KHIDI, the ‘KHIDI-AZ Diabetes Research Support Program’ was designed to enhance the medical science capabilities of domestic researchers and activate research on diabetes, aiming to improve the health of patients with diabetes and endocrine metabolic diseases. Over two years since its inception, a total of seven research projects have been selected. Among the four completed projects, achievements include ▲publication of SCI papers ▲presentations at the official international conference of the Korean Diabetes Association and the Asian Diabetes Research Federation conference ▲publication in the Korean Diabetes Association journal.

Kim Sang-pyo, CEO of Korea AZ, stated, "Korea AZ aims to create scientific achievements with domestic scientists and researchers based on an active open innovation strategy, thereby contributing to better daily lives for patients. We will continue to expand our research areas beyond diabetes to include anticancer drugs through ongoing open innovation and strive to produce meaningful results continuously."

A representative from KHIDI said, "The projects selected in the previous diabetes research support call have shown results such as presentations at prestigious international conferences and entry into clinical research. We hope that the 3rd diabetes research support call will be a valuable opportunity to support the growth and development of domestic researchers with excellent research capabilities. KHIDI will continue to actively support the discovery of research outcomes that help treat and manage diseases causing difficulties for domestic patients, including diabetes."

Meanwhile, Korea AZ and KHIDI also operate the ‘KHIDI-AZ Anticancer Research Support Program’ to support cancer research, which was the leading cause of death in Korea as of last year, in addition to the diabetes research support program.

Korea AstraZeneca-Korea Health Industry Development Institute (KHIDI), 3rd ‘KHIDI-AZ Diabetes Research Support Program’ poster. [Image provided by Korea AstraZeneca]